Valuation: Resverlogix Corp.

Market Cap 18.12M 12.69M 11.52M 10.64M 9.61M 1.2B 18.77M 128M 50.63M 639M 47.64M 46.63M 2.03B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 104M 72.76M 66.07M 61.01M 55.1M 6.86B 108M 733M 290M 3.67B 273M 267M 11.63B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.44%
Yield 2024 *
-
Yield 2025 -
1 month-11.76%
3 months-28.57%
6 months-21.05%
Current year-25.00%
1 week 0.08
Extreme 0.075
0.08
1 month 0.06
Extreme 0.06
0.09
Current year 0.06
Extreme 0.06
0.14
1 year 0.06
Extreme 0.06
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 2003-04-24
Director of Finance/CFO 78 2009-10-28
Chief Tech/Sci/R&D Officer - 2022-08-14
Director TitleAgeSince
Chairman - 2016-04-03
Director/Board Member 56 2009-10-14
Director/Board Member 66 2010-09-28
Date Insider Type Main position Quantity % Market Cap. Importance
7/6/26 Option

Chief Financial Officer

350,000 0.1018%
7/6/26 Option

Chief Financial Officer

-350,000 0.1018%
7/6/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-25.00%+7.14% 18.12M
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -0.55%+0.04%+31.49%+170.49% 41B
Weighted average by Cap. -0.83%+0.20%+37.22%+162.18%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.35M -4.86M -4.48M -4.05M -504M -7.91M -53.87M -21.34M -269M -20.07M -19.65M -854M -7.77M -5.44M -4.94M -4.56M -4.12M -513M -8.05M -54.8M -21.7M -274M -20.42M -19.99M -869M
Net Debt 81.87M 57.33M 52.06M 48.07M 43.41M 5.41B 84.81M 578M 229M 2.89B 215M 211M 9.16B 85.79M 60.07M 54.55M 50.37M 45.49M 5.66B 88.86M 605M 240M 3.03B 226M 221M 9.6B
Projected Income Statement - Annual - Resverlogix Corp.
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
26-11-13 CA$0.0750 0.00% 36,000
26-11-12 CA$0.0750 -6.25% 7,689
26-11-10 CA$0.0800 0.00% 5,000
26-11-09 CA$0.0800 +6.67% 70,380
26-11-06 CA$0.0750 +7.14% 46,600